Correspondence 0001193125-23-016222 from NewAmsterdam Pharma Co N.V. (NAMS, NAMSW) (CIK 0001936258) (NAMS)
NewAmsterdam Pharma Co N.V. (NAMS, NAMSW) (CIK 0001936258)
Date: Jan. 26, 2023 · CIK: 0001936258 · Accession: 0001193125-23-016222
AI Filing Summary & Sentiment
File numbers found in text: 333-268888
Letter
NewAmsterdam Pharma Company N.V.
Gooimeer 2-35
1411 DC Naarden
The Netherlands
January 26, 2023
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-3561
Attn: Cindy Polynice
Joe McCann
Re:
NewAmsterdam Pharma Company N.V.
Amendment No. 1 to Registration Statement on Form F-1
Filed January 17, 2023
File No. 333-268888
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), NewAmsterdam Pharma Company N.V. (the “Company”) hereby respectfully requests that the effective date of the above-referenced Registration Statement on Form F-1 (the “Registration Statement”) be accelerated by the Securities and Exchange Commission so that the Registration Statement will be declared effective under the Securities Act at 4:00 p.m. Eastern Time on January 30, 2023, or as soon thereafter as is practicable, or such other time as the Company or its counsel, Covington & Burling LLP, may request by telephone that such Registration Statement be declared effective.
We respectfully request that we be notified of such effectiveness by a telephone call to Kerry S. Burke of Covington & Burling LLP at (202) 662-5297 and that such effectiveness also be confirmed in writing.
Respectfully,
NewAmsterdam Pharma Company N.V.
Show Raw Text
CORRESP 1 filename1.htm CORRESP NewAmsterdam Pharma Company N.V. Gooimeer 2-35 1411 DC Naarden The Netherlands January 26, 2023 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3561 Attn: Cindy Polynice Joe McCann Re: NewAmsterdam Pharma Company N.V. Amendment No. 1 to Registration Statement on Form F-1 Filed January 17, 2023 File No. 333-268888 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), NewAmsterdam Pharma Company N.V. (the “Company”) hereby respectfully requests that the effective date of the above-referenced Registration Statement on Form F-1 (the “Registration Statement”) be accelerated by the Securities and Exchange Commission so that the Registration Statement will be declared effective under the Securities Act at 4:00 p.m. Eastern Time on January 30, 2023, or as soon thereafter as is practicable, or such other time as the Company or its counsel, Covington & Burling LLP, may request by telephone that such Registration Statement be declared effective. We respectfully request that we be notified of such effectiveness by a telephone call to Kerry S. Burke of Covington & Burling LLP at (202) 662-5297 and that such effectiveness also be confirmed in writing. Respectfully, NewAmsterdam Pharma Company N.V. By: /s/ Michael Davidson Name: Michael Davidson Title: Chief Executive Officer and Executive Director cc: Kerry S. Burke, Covington & Burling LLP